Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Rosetta Genomics Inks Deal to Sell PersonalizeDx for $2.9M

Rosetta Genomics Inks Deal to Sell PersonalizeDx for $2.9M

Sep 08, 2017
|
staff reporter

NEW YORK (GenomeWeb) – Rosetta Genomics said today that it has agreed to sell its PersonalizeDx unit to healthcare business group Pragmin Prognosis for $2.9 million in cash.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. BARDA Awards $5.4M to Luminex for Expanded Respiratory Panel With Coronavirus Target

  2. Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

  3. Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

  4. United Airlines Launches COVID-19 Testing Program for Travelers to Hawaii

  5. BGI Genomics Gets CE Mark for Multiplexed SARS-CoV-2, Influenza Tests

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.